Aug 4, 2026
As bispecific antibodies (BsAbs) become more integrated into oncology care, much of the focus has been placed on clinical protocols and operational readiness. However, less attention has been paid to the patient and caregiver experience. In this episode, CANCER BUZZ explores how it feels physically and emotionally for...
Jul 29, 2026
In this episode of Oncology Unscripted, hosts Mark Liu and
Deirdre Saulet speak
with Arif Kamal, MD, Chief Patient Officer at the American Cancer
Society (ACS). Dr. Kamal
discusses his recent appointment to this inaugural role at ACS,
leading into a conversation
about how he expects the cancer care field to evolve....
Jul 23, 2026
Oncolytic viruses are a novel and effective way to treat cancers by infecting and destroying cancer cells, but clinical delivery necessitates creative strategies to account for the required safety protocols, deep-freeze storage, and rigorous clinical oversight. The University of North Carolina (UNC) Lineberger...
Jul 15, 2026
In 2025, the FDA approved the antibody-drug conjugate (ADC) enfortumab vedotin combined with pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer, unlocking a new perioperative treatment option. To administer this ADC-based therapy alongside surgical intervention, multidisciplinary...
Jul 8, 2026
At the University of California, San Francisco (UCSF), the team treating patients with bladder cancer and other genitourinary malignancies utilizes a multidisciplinary team approach to ensure care is coordinated, personalized, and patient-centered. This is particularly important when administering antibody-drug...